Scholarlink

Background <p>Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI.</p> Methods <p>Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool.</p> Results <p>Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2–5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2–5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury.</p> Conclusion <p>CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2–5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cerebral embolic protection in transcatheter aortic valve implantation (TAVI): a pooled analysis of 4091 patients

  • 期刊论文

  • 发表日期：

    2025年5月10日

查看全文
  • Mahmoud Balata,
  • Mohamed Ibrahim Gbreel,
  • Mohamed Hamouda Elkasaby,
  • Ahmed Samy Badran,
  • Marwa Hassan,
  • Ralf Westenfeld,
  • Roman Pfister,
  • Sebastian Zimmer,
  • Marc Ulrich Becher,
  • Georg Nickenig,
  • Atsushi Sugiura

摘要

Background

Transcatheter aortic valve implantation (TAVI) is increasingly used for severe aortic stenosis, but debris embolization during the procedure can lead to strokes, impacting survival and quality of life. The role of cerebral embolic protection devices (CEPDs) in mitigating stroke risk remains debated. We aim to evaluate the impact of CEPDs on the risk of stroke and neurocognitive outcomes after TAVI.

Methods

Six databases (PubMed, Scopus, Web of Science, Cochrane, Embase, and Ovid) were searched until 20 January 2023. Original randomized controlled trials (RCTs) were only included and critically appraised using the Cochrane risk of bias (ROB) tool.

Results

Seven RCTs (4091 patients) were analyzed. CEPDs significantly reduced the risk of disabling stroke within 2–5 days post-TAVI (relative risk = 0.455, 95% CI: [0.214, 0.967]; p = 0.041). However, there was no significant difference in disabling stroke risk between the two groups at the 30-day follow-up (relative risk = 1.295, 95% CI: [0.373, 4.493]; p = 0.684). No significant differences were observed in non-disabling or overall stroke rates at 2–5 days, 30 days, or 90 days. Additionally, CEPDs did not significantly affect risks of life-threatening bleeding, major vascular complications, mortality, or acute kidney injury.

Conclusion

CEPDs are effective in reducing disabling stroke risk in the immediate post-TAVI period (2–5 days) but did not significantly affect the rates of non-disabling stroke, overall stroke, or disabling stroke after 30 days when compared to non-CEPD use. These findings suggest that CEPDs may offer short-term neuroprotection.